LPCN vs. CRVO, PYXS, TELO, EPIX, JSPR, ADAP, IMAB, STRO, IGMS, and ZURA
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include CervoMed (CRVO), Pyxis Oncology (PYXS), Telomir Pharmaceuticals (TELO), ESSA Pharma (EPIX), Jasper Therapeutics (JSPR), Adaptimmune Therapeutics (ADAP), I-Mab (IMAB), Sutro Biopharma (STRO), IGM Biosciences (IGMS), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs.
Lipocine (NASDAQ:LPCN) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.
9.1% of Lipocine shares are held by institutional investors. Comparatively, 25.1% of CervoMed shares are held by institutional investors. 6.1% of Lipocine shares are held by company insiders. Comparatively, 35.4% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Lipocine has a net margin of 0.00% compared to CervoMed's net margin of -118.68%. Lipocine's return on equity of -19.17% beat CervoMed's return on equity.
Lipocine has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500.
Lipocine received 322 more outperform votes than CervoMed when rated by MarketBeat users. However, 83.33% of users gave CervoMed an outperform vote while only 66.73% of users gave Lipocine an outperform vote.
Lipocine currently has a consensus target price of $10.00, indicating a potential upside of 176.24%. CervoMed has a consensus target price of $27.63, indicating a potential upside of 224.62%. Given CervoMed's higher possible upside, analysts plainly believe CervoMed is more favorable than Lipocine.
CervoMed has higher revenue and earnings than Lipocine. CervoMed is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.
In the previous week, CervoMed had 12 more articles in the media than Lipocine. MarketBeat recorded 13 mentions for CervoMed and 1 mentions for Lipocine. CervoMed's average media sentiment score of 0.24 beat Lipocine's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.
Summary
CervoMed beats Lipocine on 12 of the 19 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy LPCN Stock Free LPCN Stock Alerts